Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
home
home
Roivant Sciences
Roivant Sciences
Health
How a 32-Year-Old CEO Got a Team of Pharma Vets to Join His Radical Approach to Making Drugs
By
Staff Writer
September 21, 2017
Health
Why SoftBank Made a Record-Breaking $1.1 Billion Bet on This Biotech Firm
By
Digital Assets Editor
August 9, 2017
Health
This 31-Year-Old CEO Is Snapping Up Drug Industry Veterans Left and Right
By
Investment Desk
July 10, 2017
Health
This 31-Year-Old Just Launched His 5th Biotech Company With a Boost From Merck
By
Industry Analyst
June 6, 2017
Most Popular
AI
Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
By
Editorial Team
Big Tech
Nvidia CEO says the company is in a no-win situation amid AI-bubble chatter, leaked meeting reveals
By
Financial Writer
Travel & Leisure
Transportation chief offers advice to increasingly angry Americans: ‘Let’s maybe go back to an era where we didn’t wear...
By
Research Team